These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27528266)

  • 21. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
    Singh N; Dubey S; Chinnaraj S; Golani A; Maitra A
    Mol Diagn Ther; 2009; 13(1):49-58. PubMed ID: 19351215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
    Balhara A; Singh S
    Pharm Res; 2021 Sep; 38(9):1485-1496. PubMed ID: 34518943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
    Lee J; Choi G; Yang S; Ha JE; Kim ES; Park JS; Lee K; Song J; Lee JH; Lee JI
    Tuberculosis (Edinb); 2021 Mar; 127():102052. PubMed ID: 33548864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
    Salazar-González R; Gómez R; Romano-Moreno S; Medellín-Garibay S; Núñez-Ruíz A; Magaña-Aquino M; Milán-Segovia RC; Portales-Pérez DP
    Mol Biol Rep; 2014 Dec; 41(12):7833-43. PubMed ID: 25163630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Int J Clin Pharm; 2020 Aug; 42(4):1217-1226. PubMed ID: 32638292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
    Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
    Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
    Béranger A; Bekker A; Solans BP; Cotton MF; Mirochnick M; Violari A; Wang J; Cababasay M; Wiesner L; Browning R; Moye J; Capparelli EV; Savic RM
    Clin Infect Dis; 2022 Sep; 75(6):1037-1045. PubMed ID: 35134861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia.
    Fredj NB; Romdhane HB; Woillard JB; Chickaid M; Fadhel NB; Chadly Z; Chaabane A; Boughattas N; Aouam K
    Int J Infect Dis; 2021 Mar; 104():562-567. PubMed ID: 33476758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytochrome P450 and NAT2 polymorphisms and drug metabolism in DOTS].
    Castillejos-López Mde J; García-Sancho MC; Quiñones-Falconi F; Pérez-Padilla JR
    Rev Invest Clin; 2008; 60(1):47-57. PubMed ID: 18589587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoniazid acetylation metabolic ratio during maturation in children.
    Pariente-Khayat A; Rey E; Gendrel D; Vauzelle-Kervroëdan F; Crémier O; d'Athis P; Badoual J; Olive G; Pons G
    Clin Pharmacol Ther; 1997 Oct; 62(4):377-83. PubMed ID: 9357388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.
    Kubota R; Ohno M; Hasunuma T; Iijima H; Azuma J
    Eur J Clin Pharmacol; 2007 Oct; 63(10):927-33. PubMed ID: 17665185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis.
    Soedarsono S; Jayanti RP; Mertaniasih NM; Kusmiati T; Permatasari A; Indrawanto DW; Charisma AN; Yuliwulandari R; Long NP; Choi YK; Hoa PQ; Hoa PV; Cho YS; Shin JG
    Int J Infect Dis; 2022 Apr; 117():8-14. PubMed ID: 35017103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
    Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.
    Chen B; Li JH; Xu YM; Wang J; Cao XM
    Clin Chim Acta; 2006 Mar; 365(1-2):104-8. PubMed ID: 16182272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of NAT2 acetylation status in the Greenlandic population.
    Geller F; Soborg B; Koch A; Michelsen SW; Bjorn-Mortensen K; Carstensen L; Birch E; Nordholm AC; Johansen MM; Børresen ML; Feenstra B; Melbye M
    Arch Toxicol; 2016 Apr; 90(4):883-9. PubMed ID: 25794903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1.
    Salazar-González RA; Turiján-Espinoza E; Hein DW; Milán-Segovia RC; Uresti-Rivera EE; Portales-Pérez DP
    Biochem Pharmacol; 2018 Oct; 156():340-347. PubMed ID: 30149019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
    Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
    J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
    Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
    Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.